Novosanis’ medical device Colli-Pee™ US FDA listed
You are here
Wijnegem, Belgium, November 14th 2016: Novosanis, announced today that Colli-Pee™, a self-sampling device suited for standardized and volumetric first-void urine collection has been US FDA listed.
“The listing of Colli-Pee in the US is a major milestone in Novosanis’ history. This opens new opportunities to collaborate with diagnostic companies, suppliers of diagnostic tests, laboratories and hospitals in the US. The Colli-Pee device allows for collection of standardized and volumetric first-void urine making the sample highly suited for detection of infectious diseases, like Human Papilloma Virus and other sexually transmitted infections, but also biomarkers for detection of early stage cancer.” says Vanessa Vankerckhoven, CEO Novosanis, Belgium.